Report Details:
15 Companies Covered
126 Pages
Market Research Future (MRFR) has published a comprehensive research report on the global Chemotherapy Market. The market is valued at USD 32.18 billion in 2025 and is projected to grow at a robust growth rate of 10.21% during the forecast period of 2026-2035, reaching USD 80.45 billion by 2035.
The steady growth in worldwide cancer incidence, along with the acceleration of biosimilar adoption, the reduction of treatment costs, and the growing patient preference for oral formulations that enable cytotoxic drug therapy to be administered at home, are reshaping the market.
Market Overview
As healthcare systems worldwide strive to provide effective regimens of antineoplastic treatment at scale, chemotherapy remains a key pillar of oncology care. The intersection of biosimilar competition, innovation in oral cytotoxic drug therapy and government investment in cancer infrastructure is changing the landscape of cytotoxic agent prescribing and administration, creating a strong growth environment for pharmaceutical manufacturers globally.
The North America market is expected to hold a major share of the global market owing to high oncology spend per capita and extensive payer coverage. Europe accounts for around 26.8% of the global market, supported by unified EMA approval routes and biosimilar adoption. The fastest-growing region is identified as Asia-Pacific, with an anticipated growth of 11.14% CAGR through 2035. The growth is powered by healthcare infrastructure build-outs in China and India.
Key Market Trends & Growth Drivers
Rising Global Cancer Incidence: The GLOBOCAN 2024 report projects the number of new cancer cases to reach 35 million per year by 2050, up from 20 million in 2022, with the greatest increase in low- and middle-income nations. For around 60% of solid tumor patients that do not respond to precision treatments alone, first-line and salvage chemotherapy remain essential.
- Biosimilar Adoption Cutting Treatment Costs: The competitive generic environment in Europe’s centralized and regional tender systems for traditional platinum-based cancer therapies has led to plummeting per-cycle infusion costs. The consequent price cuts have structurally raised therapeutic volumes, allowing more and more public hospitals to include standard intravenous chemotherapy protocols in local regional formularies.
- Oral Formulation Growth: Oral antineoplastics, led by the likes of capecitabine, temozolomide and lenalidomide, already command a commanding proportion of the oncology market by route of administration. The pipeline for developing new oral prodrug forms is specifically geared to move the balance of treatment from the highly resource-intensive hospital-based oncology infusion suite to the home.
- Government Oncology Funding Programs: Emerging economies are actively supporting the demand floor for cytotoxic drug therapies by allocating substantial national healthcare assets to oncology infrastructure. India’s Ayushman Bharat oncology growth, the EU Beating Cancer Plan’s EUR 4 billion commitment, and China’s Healthy China 2030 plan ensure high-volume procurement that insulates key chemotherapy markets from localized macroeconomic turbulence.
- Fixed-Dose Combination Regimens: Fixed-Dose Combination Regimens: Multi-agent fixed-dose combinations and antibody-drug conjugates delivering cytotoxic payloads are progressively replacing legacy single-agent IV chemotherapy regimens. The FDA approved 14 combination chemotherapy indications from 2022 to 2024 alone, lowering the cost per cycle and extending the number of patients who could receive treatment.
Market Segmentation Insights
By Drug Class: Alkylating agents are estimated to account for ~40.8% of the market in 2025 due to their basic function in combination antineoplastic treatment regimens for solid tumors and hematologic malignancies. Antimetabolites are anticipated to increase at a CAGR of 10.75% up to 2035 due to the increased use of capecitabine and pemetrexed in oral cytotoxic drug therapy schedules.
By Route of Administration: Patient preference is increasingly shifting towards at-home dosage over hospital-based oncology drug infusion, with oral treatments driving the Chemotherapy Market at 54.3% by 2025. The IV chemo procedures are expected to grow at 10.85% CAGR, driven by newer platinum-based cancer medicines and antibody-drug conjugates approvals.
By Indication: In 2025, blood cancers contributed USD 8.05 billion to the Chemotherapy Market, driven by multi-agent protocols for acute leukemias. In addition, neoadjuvant and adjuvant chemotherapy regimens have been confirmed in trials. Hence, breast cancer treatments are expected to register a CAGR of 10.95% by 2035. Lung cancer has the highest single-indication share of 27.8%, mirroring the persistent reliance on platinum-doublet intravenous chemo regimens as first-line therapy.
By End User: Hospitals and Clinics, by End User, hold the lion’s share of the Chemotherapy Market, reflecting the capital intensity and specialized infrastructure necessary to provide the intravenous chemo regimen. Specialty Centers are the fastest expanding segment as oral cytotoxic drug therapy and home-delivery platforms increase access outside the typical hospital infusion setting.
Regional Landscape
North America -- Technology Adoption Leader
North America leads the Chemotherapy industry, accounting for a 41.2% share of the industry. Growth is being driven by high oncology spend per capita, wide payer coverage and the 340B Drug Pricing Program, which allows safety-net hospitals to purchase antineoplastic therapy regimens at a discount. The United States leads the area, with CMS reimbursement adjustments for 2024 increasing the average payout for cytotoxic drug therapy delivery by 3.2%. Canada also contributes significantly with expansions to the Pan-Canadian Oncology Drug Review contributing to a CAGR of 10.85%. Mexico is a growing high-growth market with Seguro Popular cancer-coverage legislation extending access to intravenous chemo regimens.
Europe -- Emerging Market Dynamics
The global market is estimated to be approximately 26.8% Europe-driven by the standardised EMA approval procedures, adoption of biosimilars and the EUR 4 billion commitment in the EU Beating Cancer Plan. Germany is the regional leader, with its statutory health insurance system covering practically all agents for approved cytotoxic drug therapy and being the greatest single-country contributor in Europe. The UK, France and Italy follow, with the NHS Cancer Drugs Fund allocating GBP 1.4 billion in 2024 to facilitate fast-track access to new antineoplastic treatment protocols. Key businesses like F. Hoffmann-La Roche, Novartis AG and others are pushing innovation. The competition is also heating up with the expanding base of generics makers.
Asia-Pacific -- Rapid Growth and Innovation
Asia-Pacific is the fastest-growing region in the Chemotherapy Market, expected to increase at a CAGR of 11.14% through 2035. The growth is powered by the rapid rate of digitization, government hospital expansion initiatives and increasing cancer incidence, especially in China and India. The Chemotherapy Market in China is the largest in the region by revenue, with 22 entries of antineoplastic treatment regimens onto China’s National Reimbursement Drug List between 2022 and 2024. India’s bulk API manufacturing capacity is over 40% of global cytotoxic active ingredients and is a hub of both demand and supply. Japan and South Korea lead biosimilar uptake and HIRA reimbursement reforms to cytotoxic drug therapy.
Middle East and Africa -- Untapped Market Potential\
Middle East and Africa has a lower but fast-growing part of the global market for cancer treatment solutions. Growth in the area is driven by increased investment in healthcare infrastructure and growing demand for cancer treatment solutions. Saudi Arabia’s Vision 2030 health-sector investments include USD 3.2 billion for comprehensive cancer centers that will offer full-spectrum antineoplastic treatment regimens. The UAE is building on its position as a medical-tourism destination and the growing need for oncology medicine infusion services. Egypt’s national hepatitis-C screening infrastructure is being repurposed to detect cancer earlier, funneling newly diagnosed patients into the chemotherapy market at earlier, more curable stages.
Competitive Landscape
The Chemotherapy Market is moderately concentrated, with the top 5 companies holding an estimated revenue share of 35--42%. The key players are F. Hoffmann-La Roche, Pfizer Inc., Bristol-Myers Squibb, Novartis AG, Teva Pharmaceutical, Cipla Ltd., Sun Pharmaceutical, Mylan (Viatris), Eli Lilly & Co., and Fresenius Kabi. Recent key developments include:
- Pfizer Inc. announced a major oncology collaboration with Innovent Biologics in 2026, valued at up to USD 10.5 billion, to jointly develop 12 early-stage cancer therapies including antibody-drug conjugates (ADCs) and multispecific antibodies, strengthening its chemotherapy and oncology pipeline.
- Novartis AG reported promising early-stage results in 2026 for its experimental actinium-based radiopharmaceutical therapy for prostate cancer, showing strong anti-tumor activity even in patients previously treated with chemotherapy, further expanding its oncology and radioligand therapy portfolio.
Future Outlook
The Chemotherapy Market is likely to be changed by 2035 with additional advancement in antibody-drug conjugate hybrid regimens, expanded AI-optimized dose and treatment scheduling, and further penetration into emerging markets throughout Asia-Pacific, the Middle East, and Africa. Companies that are working on oral chemotherapy home-delivery platforms, supply-chain regionalization and API sovereignty, and ESG-focused green chemistry in cytotoxic manufacture are well positioned to capture disproportionate growth.
The MRFR report points out the following key growth opportunities: the integration of AI-driven precision dosing for enhanced patient safety; the development of emerging-market cancer-center build-out strategies; and tailored chemotherapy expansion in high-growth regions where government oncology funding programs guarantee baseline demand for cytotoxic drug therapy.
